Multiclass <scp>HCV</scp> resistance to direct‐acting antiviral failure in real‐life patients advocates for tailored second‐line therapiesVelia Chiara Di Maio, Francesca Ceccherini‐Silberstein, Valeria Cento et al.|Liver International|2017Cited by 90
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1–4 in ItalyAda Bertoli, Alessia Ciancio, Savino Bruno et al.|Scientific Reports|2018Cited by 48
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?Velia Chiara Di Maio, L. Lambiase, Valeria Cento et al.|Journal of Hepatology|2017Cited by 31
Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimenAdolfo de Salazar, Eiko Schnaitmann, Julia Dietz et al.|Journal of Antimicrobial Chemotherapy|2020Cited by 22
A Boceprevir Failure in a Patient Infected with HCV Genotype 1G: Importance and Limitations of Virus Genotyping Prior to HCV Protease-Inhibitor-Based TherapyValeria Cento, Francesca Ceccherini‐Silberstein, Simona Landonio et al.|Antiviral Therapy|2013Cited by 19